CELL INTELLIGENCE · 肿瘤细胞治疗研究

CD70 靶向 HIT-CAR-T 细胞对乳腺癌患者来源异种移植瘤的控制

Control of breast cancer patient-derived xenografts by CD70-targeted HIT-CAR T cells.

Anti-hCD70 CAR transduced PBL（CAR-T 细胞）治疗胰腺癌、恶性肿瘤：I/II 期临床试验

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

这是一项 I/II 期、非随机的注册临床试验，评估 CAR-T 细胞治疗胰腺癌、恶性肿瘤、乳腺癌的疗效与安全性。研究设计：非随机、2 个分组。当前状态：招募中。计划入组 124 例。试验地点：美国 · 贝塞斯达（共 1 个中心）。登记号：NCT02830724。

嵌合抗原受体自然杀伤（CAR-NK）细胞治疗乳腺癌的疗效与安全性评价：系统综述与荟萃分析

Evaluation of Efficacy and Safety of Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cells in Breast Cancer: A Systematic Review and Meta-Analysis.